Comprehensive Study Notes on General Anesthetics

Fundamental Principles and Potency of General Anesthetics

  • Minimum Alveolar Concentration (MAC):

    • MAC is defined as the concentration of an anesthetic at which 50%50\% of patients do not respond to a surgical incision.

    • There is an inverse relationship between MAC and potency; a lower MAC indicates a higher potency, whereas a high MAC value indicates a poorer anesthetic effect.

    • MAC is influenced by factors such as body temperature, age, and concurrent use of other drugs.

    • Nitrous oxide (N2ON_2O) has a very high MAC value (exceeding 100%100\%), making it relatively weak as a primary anesthetic agent compared to volatile liquids like Halothane.

  • Solubility and Partition Coefficients:

    • Blood-Gas Partition Coefficient: This determines the rate of induction and recovery. A smaller coefficient means the drug is less soluble in the blood, allowing the partial pressure in the alveoli and blood to reach equilibrium faster, leading to a more rapid onset of action (induction) and a faster recovery.

    • Oil-Gas Partition Coefficient: Inversely related to MAC; agents with higher lipid solubility (larger oil-gas coefficient) are generally more potent.

    • Highly lipid-soluble anesthetics do not necessarily require a higher concentration; rather, as lipid solubility increases, the concentration required for anesthesia generally decreases.

  • General Characteristics:

    • Gaseous anesthetics easily cross the placental barrier and can enter the fetus.

    • N2ON_2O can be used to accelerate the induction of other anesthetics (such as Halothane) due to the second gas effect.

Stages and Signs of General Anesthesia

  • Stage I: Analgesia: The patient experiences a loss of pain sensation but remains conscious.

  • Stage II: Delirium (Excitement): Characterized by irregular breathing, increased muscle tone, and the first instance of pupil dilation.

  • Stage III: Surgical Anesthesia:

    • This stage is characterized by the loss of consciousness, loss of reflex functions, and skeletal muscle relaxation.

    • Level 2 of Stage III: Specific signs include the second occurrence of pupil dilation and dryness of the eyes.

  • Stage IV: Medullary Paralysis: This is a critical stage where respiratory and circulatory centers in the medulla are inhibited, which can lead to death if not managed immediately.

Inhalation Anesthetics: Properties and Adverse Effects

  • Halothane:

    • Classification: Inhalation liquid anesthetic.

    • Properties: High potency, but exhibits poor analgesic properties and poor skeletal muscle relaxation.

    • Side Effects: Can cause bradycardia (slowed heart rate), hypotension (decreased blood pressure), and decreased cardiac output.

    • Toxicities: It has the highest risk of hepatotoxicity (liver damage) among common anesthetics. It is also associated with Malignant Hyperthermia.

    • Cardiac Sensitization: It sensitizes the heart to catecholamines (like epinephrine), which can lead to dangerous cardiac arrhythmias or even cardiac arrest if epinephrine is administered concurrently.

    • Post-operative effect: Less likely to cause post-operative vomiting compared to agents like Ether.

  • Nitrous Oxide (N2ON_2O; Laughing Gas):

    • Properties: Fast-acting induction and recovery, non-flammable, and possesses excellent analgesic properties. However, it provides poor skeletal muscle relaxation and has low anesthetic potency (high MAC).

  • Methoxyflurane:

    • Noted for having the highest potential for nephrotoxicity (kidney damage) because of the release of fluoride ions during metabolism.

  • Enflurane:

    • Provides good skeletal muscle relaxation.

  • Isoflurane:

    • A commonly used stable inhalation agent; less likely to cause arrhythmias compared to Halothane.

  • Cyclopropane:

    • Noted for being highly flammable and explosive, which severely limits its clinical use.

  • Ether (Diethyl Ether):

    • Notorious for causing significant post-operative nausea and vomiting.

Intravenous (IV) Anesthetics

  • Thiopental:

    • Classification: Ultra-short-acting Barbiturate.

    • Mechanism of Action Termination: Its effect is terminated not by rapid metabolism or excretion, but by Redistribution. After injection, the drug level in the brain drops rapidly as it redistributes from the brain (high-blood-flow area) to lipid-rich adipose tissues.

    • Clinical Use: Often used for rapid induction of anesthesia before switching to inhalation agents.

  • Ketamine:

    • Classification: Dissociative anesthetic; acts as an NMDA receptor antagonist.

    • Effects: Induces a state of "dissociative anesthesia" (the patient appears awake but is unconscious and feels no pain). It stimulates the sympathetic nervous system, leading to increased heart rate and blood pressure.

    • Contraindications: It increases intracranial pressure, making it contraindicated for patients with Central Nervous System (CNS) tumors.

    • Respiratory Impact: Unlike many other anesthetics, it causes less respiratory depression.

  • Etomidate:

    • Clinical Limitation: Its use is strictly limited because it inhibits the production of adrenal steroids (adrenal suppression).

  • Propofol:

    • An intravenous anesthetic used for both induction and maintenance of anesthesia.

Premedication and Adjunct Drugs

  • Anticholinergics (e.g., Atropine):

    • Purpose: Administered before surgery to reduce salvage and bronchial secretions (preventing aspiration), and to protect against reflex bradycardia.

  • Benzodiazepines (e.g., Diazepam, Midazolam):

    • Purpose: Used to relieve patient anxiety, induce sedation, and can prevent convulsions associated with high doses of local anesthetics.

  • Opioids (e.g., Meperidine/Demerol, Fentanyl):

    • Purpose: Primarily used for analgesia (pain relief) before or during surgery.

  • Antihistamines (e.g., Hydroxyzine):

    • Purpose: Provides sedation and antiemetic (anti-vomiting) effects.

  • Muscle Relaxants (e.g., Succinylcholine):

    • Used to achieve skeletal muscle relaxation. When combined specifically with Halothane, there is a significantly increased risk of developing Malignant Hyperthermia.

  • Drugs NOT typically used as premedication: Anti-adrenergics.

Clinical Warnings and Specific Conditions

  • Malignant Hyperthermia: A life-threatening hypermetabolic state often triggered by the combination of volatile inhalation anesthetics (like Halothane or Enflurane) and the depolarizing muscle relaxant Succinylcholine.

  • Post-Operative Nausea and Vomiting (PONV): Highly associated with Ether and Cyclopropane; less common with Halothane.

  • Adrenal Suppression: Specifically associated with Etomidate.

  • Nephrotoxicity: Primarily a concern with Methoxyflurane due to fluoride metabolites.